Search for Clinical Trial Results

Sponsored By

Pyoderma Gangrenosum - 4 Studies Found

Status Study
Completed Study Name: Spesolimab in Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2025-11-04
Interventions: 900 mg of spesolimab intravenously (IV) administered at Weeks 0, 3, 6, 9, 12 and 15.
Completed Study Name: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Condition: Pyoderma Gangrenosum
Date: 2025-11-04
Interventions: Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
NOT_YET_RECRUITING Study Name: Deucravacitinib in PG
Condition: Pyoderma Gangrenosum
Date: 2025-11-04
Interventions: 6 mg tablet
Completed Study Name: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Date: 2025-11-04
Interventions: vilobelimab infusion